Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1998

View Archived Issues

Pharmacological profile of new alkylating agent from Menarini

Company Profile: Ribozyme

Company Profile: Onyx

FDA advisory panel recommends Apligraf

Synthelabo claims mixed and specific dopamine receptor ligands

New analgesic agents from Gruenenthal

Heterocyclic bradykinin antagonists in development at Hoechst Marion Roussel

BASF presents new ET antagonists

Newly identified human natural killer cell-activating factor reported by HGS

Yeda patents IFN-alpha/beta receptor-neutralizing antibodies

EPO peptides and anti-EPO antibodies from Behringwerke

Anti-ErbB3 antibodies described by Genentech in patent literature

Lactoferrin use in heparin neutralization described

Anxiolytic candidate with favorable pharmacokinetic properties developed at Warner-Lambert

Trovan soon to be available in pharmacies

Androtab-SL NDA is inadequate for approval, FDA says

PB-005 studied in postsurgical wound healing

Second-generation DHEA derivative in development at Pharmadigm

Potent antiretroviral activity shown for abacavir + protease inhibitor in HIV-positive patients

Shaman suspends phase II trial of Virend

Tasmar cleared by FDA

Promising efficacy reported at AIDS conference for amprenavir combinations

Crescendo and Alza to collaborate on chronic pain product

TheraTech and SmithKline Beecham join forces on nicotine product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...